Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, used for the treatment of non-small cell lung cancer (NSCLC).
Purity:
95.00%
CAS Number:
[2428381-53-5]
Target:
VEGFR|||PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted